- HOME
- ABOUT DCTD
- DCTD INITIATIVES
- SCIENTIFIC ACCOMPLISHMENTS
- CALENDAR OF EVENTS

DCTD Programs

- Cancer Diagnosis Program
- Cancer Imaging Program
- Cancer Therapy Evaluation Program
- Developmental Therapeutics Program
- Radiation Research Program
- Biometric Research Branch

National Lung Screening Trial (NLST)

Digital Mammographic Imaging Screening Trial (DMIST)

DCTD CALENDAR OF EVENTS

Sixth National Forum on Biomedical Imaging in Oncology
April 7-8, 2005
Hyatt Regency Bethesda
Bethesda, Maryland

For further information, please contact Teresa Zuber at zubert@mail.nih.gov or 301.435.4490.

Additional Links

- Interagency Council on Biomedical Imaging in Oncology
- 2004 National Forum and Workshop on Biomedical Imaging in Oncology
- 2003 National Forum and Workshop on Biomedical Imaging in Oncology
- 2002 National Forum and Workshop on Biomedical Imaging in Oncology
- 2000 National Forum and Workshop on Biomedical Imaging in Oncology
- 1999 NCI-Industry Forum and Workshop on Biomedical Imaging in Oncology

Dear MR workshop participant,

Thank you for registering with us for the **"MR Workshop on Translational Research in Cancer - Tumor Response",** to be held at the Hyatt Regency Hotel in Bethesda, MD, on November 22-23, 2004. We thought it would be helpful to distribute in advance some background materials and a bibliography we think might be important for the topics we are going to discuss at the workshop.
For your convenience, please find attached the following:

1)Abstract for a previous NCI-sponsored workshop on DCE-MRI held in October 1999
2)Abstract, Proc. ISMRM 2003, PTAC Cancer Research UK
3)Related Literature: DCE-MRI to monitor cancer treatments in patients
4)Related Literature: MRS to monitor cancer treatments in patients
5)Related Literature: Diffusion MRI for cancer treatment in patients

Recommendations for MRS measurement methods and endpoints for use in multicenter trials of anti-cancer therapeutics

Recommendations for MR measurement methods at 1.5-Tesla and endpoints for use in Phase 1/2a trials of anti-cancer therapeutics affecting tumor vascular function